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Neurexin 1 (NRXN1) is a large presynaptic transmembrane protein that has complex and variable patterns of expression in the
brain. Sequence variants in NRXN1 are associated with differences in cognition, and with schizophrenia and autism. The murine
Nrxn1 gene is also highly polymorphic and is associated with signiﬁcant variation in expression that is under strong genetic
control. Here, we use co-expression analysis, high coverage genomic sequence, and expression quantitative trait locus (eQTL)
mapping to study the regulation of this gene in the brain. We proﬁled a family of 72 isogenic progeny strains of a cross between
C57BL/6J and DBA/2J (the BXD family) using exon arrays and massively parallel RNA sequencing. Expression of most Nrxn1
exons have high genetic correlation (r40.6) because of the segregation of a common trans eQTL on chromosome (Chr) 8 and a
common cis eQTL on Chr 17. These two loci are also linked to murine phenotypes relevant to schizophrenia and to a novel
human schizophrenia candidate gene with high neuronal expression (Pleckstrin and Sec7 domain containing 3). In both human
and mice, NRXN1 is co-expressed with numerous synaptic and cell signaling genes, and known schizophrenia candidates.
Cross-species co-expression and protein interaction network analyses identiﬁed glycogen synthase kinase 3 beta (GSK3B)a s
one of the most consistent and conserved covariates of NRXN1. By using the Molecular Genetics of Schizophrenia data set, we
wereabletotestandconﬁrmthatmarkersinNRXN1andGSK3Bhaveepistaticinteractionsinhumanpopulationsthatcanjointly
modulate risk of schizophrenia.
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Introduction
Neurexins (NRXNs) are neuronal cell adhesion proteins
inserted mainly into the presynaptic membrane. They serve
as bridging molecules that directly bind the presynaptic
neurotransmitter machinery with postsynaptic transmem-
brane proteins such as the neuroligins and neurotransmitter
receptors.
1–6 The NRXNs have an important role in regulation
of presynaptic Ca
2þ channels and neurotransmitter release,
andarealso involvedinthe modulationofpostsynaptic NMDA
and g-aminobutyric acid (A) receptor activity.
6–9
There are three members in the NRXN gene family—Nrxn1,
Nrxn2 and Nrxn3. They are among the largest of mammalian
genes, Nrxn1 being close to 1.1Mb and Nrxn2 about 1.7Mb,
and all are highly conserved across vertebrates.
10,11 A
fascinating aspect of the NRXNs is their enormously complex
and extensive alternative splicing that can potentially produce
about a thousand isoforms.
12 Each NRXN gene has two
promotersandtranscribesalongversion(a-NRXN)andashort
version (b-NRXN). Multiple isoforms of both long and short
variantsareproducedasaresultofalternativesplicingfromﬁve
splicing regions within each gene.
10,11 Deletion of the larger
a-NRXNs leads to marked deﬁcits in synaptic function.
13,14
Among the NRXN genes, NRXN1 has been implicated in
neurodevelopmentalandpsychiatricdisorders.Genome-wide
association studies have consistently found links between
copy number variation (primarily deletions) in NRXN1 and
autism and schizophrenia.
15–19 Associations have also been
found between sequence variants in NRXN1 and nicotine
addiction and alcoholism.
20–22 In mice, deletion of Nrxn1a
causes a decrease in excitatory synaptic transmission in the
hippocampus, and behavioral changes including enhance-
ment of motor learning and decreased prepulse inhibition
(PPI) to acoustic startle—an endophenotype that models
sensory-gating deﬁcits in schizophrenia.
23
These studies in human and mice have established an
important role for NRXN1 in the etiology of neuropsychiatric
diseases. However, disorders such as schizophrenia and
autism are inherentlypolygenic and emergefrom the interplay
of multiple sequence variants and environmental factors. A
high-priority candidate such as NRXN1 is bound to operate
within the context of a wider network of genes and is likely to
involve non-linear and epistatic interactions that contribute to
disease risk. Despite the importance of epistasis (gene–gene
interactions) in disease process, current large-scale genetic
studies rarely go beyond linear additive models.
24 Those that
do apply a network approach to genome-wide association
studies
25–28 rely on known protein interactions and pathways,
and are essentially constrained by prior knowledge.
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www.nature.com/tpHere, we ask whether we can use gene co-expression
analysis in the mouse to deﬁne and reﬁne genetic and
molecular networks for Nrxn1 that provide insights into
neuronal processes and possible disease mechanisms. To
whatextentcanwetranslatefrommousetohumanatthelevel
of genetic networks? Speciﬁcally, can data from a large family
of mouse strains reveal novel partners for Nrxn1 that are
relevant to human disease? The Nrxn1 locus is highly
polymorphic in the BXD family and contains several single-
nucleotide polymorphisms (SNPs) and insertions and dele-
tions. Applying a reverse complex trait approach, we have
treated these natural sequence variants and corresponding
variations in transcript abundance as a starting point in the
dissection of downstream phenotypes.
29 We used expression
QTL (eQTL) analysis to evaluate the genetic regulation of
Nrxn1 and to build an interaction network around Nrxn1 that
includes other genes and also key behavioral phenotypes.
Finally, we used human data extracted from the Molecular
Genetics of Schizophrenia (MGS) study
30 to evaluate the
translational relevance of the murine analysis and to test a
speciﬁc hypothesis about an epistatic interaction between
NRXN1 and glycogen synthase kinase 3 beta (GSK3B).
Materials and methods
Mouse strains and resources. The BXD inbred strains
were derived by crossing the parental strains C57BL/6J (B6)
and DBA/2J (D2) followed by 420 generations of
inbreeding.
31–33 The parental lines differ at approximately
4.8 million SNPs and at another 500000 insertions and
deletions and copy number variations and the family as a
whole is highly polymorphic.
34 The BXDs are a densely
phenotyped and genotyped family and have been used as a
genetic reference panel for over 30 years.
35 A compendium
of over 2000 phenotypes and over 45 microarray data sets
for these strains is available from GeneNetwork (http://
www.genenetwork.org).
For this study, transcript measurements were taken from
the hippocampi of 70 BXD strains, the parental B6 and D2,
and reciprocal F1 hybrids (B6D2F1 and D2B6F1). Details on
the strain, sex and age of each animal can be accessed from
http://www.genenetwork.org/dbdoc/UMUTAffyExon_0209_
RMA.html. The mice were bred at the University of
Tennessee Health Science Center or at the Jackson
Laboratory,BarHarbor,ME,USA.Hippocampaldissections
were carried out at UTHSC or at the Beth Israel Deaconess
Medical Center by our colleague, Dr Glenn D Rosen (details
on dissection and tissue processing are in Supplementary
methods). All animal procedures were approved by the
Animal Care and Use Committees at UTHSC and BIDMC.
Microarray data processing. To provide a comprehensive
analysis of natural variation in gene expression in the
mouse hippocampus, we have previously generated trans-
criptome proﬁles using conventional Affymetrix arrays
for B100 strains of mice.
36 In this study, we used
exon arrays (Affymetrix Exon 1.0 ST, Affymetrix, http://
www.affymetrix.com) to provide a more detailed but still
global analysis of the genetic control of alternative splicing in
the hippocampus. The Affymetrix Exon 1.0 ST arrays contain
a total of 1.2 million probe sets and uses at least four probes
to interrogate an exon. Probe level intensity values were
extracted from the CEL ﬁles using the GeneChip Operating
Software provided by Affymetrix. Probe set level
summarization and data normalization was done within
GeneChip Operating Software using the Robust Multichip
Averaging method. The expression values were then log-
transformed and stabilized to a mean of 8 and an s.d. of 2
across the samples. The entire data set (BXD hippocampus
mRNA UMUTAffy Hippocampus Exon (February 2009)
RMA) can be downloaded from GeneNetwork data sharing
site using the accession number GN206 (http://www.
genenetwork.org/share/data/).
Array data analysis on GeneNetwork. QTL mapping was
done for the probe set level data using QTL Reaper.
37,38 The
results are presented as likelihood ratio statistic (LRS) scores
(LOD score¼LRS/4.61). We used 3795 informative
microsatellite and SNP markers in the BXDs for interval
mapping. The BXD genotypes can be downloaded from
http://www.genenetwork.org/share/data/. Up to a million
permutations were performed to compute the genome-wide
suggestive and signiﬁcant thresholds. Nrxn1 is located on
chromosome (Chr) 17 between 90.432 and 91.492Mb (mm9,
build 37) on the minus strand and is targeted by 172 probe
sets. For the probe sets that targeted exons in Nrxn1 and
mapped as cis eQTL, we screened the probe sequences for
overlapping SNPs that may confound the QTL analysis.
Although Nrxn1 is SNP rich, most exons are devoid of SNPs.
With the exception of exons 5 and 17 (each harbors a
synonymous mutation), the exon targeting probe sets do not
overlap SNPs and the consistent cis effect is reliable.
For the co-expression analysis in the mouse hippocampus,
pair-wise Pearson product moment correlations were com-
puted for all probe sets based on expression variation across
the 74 lines of mice. The top 1000 probe sets correlated with
Nrxn1 were ﬁltered by expression level. Only probe sets with
expression48 ona log2 scale,and well-annotated probesets
that map to known genes were retained for subsequent
analysis. Co-expression results are presented for a repre-
sentative probe set (Affy 4930721) targeting a middle exon
(exon 12) that has high expression, is associated with both
eQTLs on Chrs 17 and 8 (see Results section), and is well
correlated with other Nrxn1 exons. Analyses using
other exons from the same correlated block of exons give
similar results. We also used a publicly available human
forebrain expression data (neocortex and hippocampus)
generated using the Affymetrix U133 Plus 2.0 arrays (GEO
accession number GSE5281).
39,40 This data set contains
samples from Alzheimer’s disease cohort and age-matched
control subjects. We computed Pearson product correlations
across 71 samples from normal subjects and retrieved the
top 1000 covariates of NRXN1 from the pool of over 54000
probe sets.
RNA sequencing. Total RNA was isolated from the
hippocampus of adult female B6 and D2 mice. Ribosomal
RNA was depleted using the RiboMinus eukaryotic kit (http://
www.invitrogen.com). We prepared multiplexed bar-coded
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Barcoding kits. Emulsion PCR was then done and libraries
were ampliﬁed and sequenced on the ABI SOLiD 3 plus
system (http://www.appliedbiosystems.com).
We generated a total of 77 million and 80 million 50
nucleotide RNA sequencing (RNA-seq) tags for B6 and D2,
respectively. Of these, approximately 58 million and 63 million
readsalignedtothemousereferencegenome(NCBI37/mm9)
using the ABI Bioscope software (http://www.solidsoftware-
tools.com). The alignment results (BAM ﬁles) were uploaded
to the Partek Genomic Suite (http://www.partek.com) and
GeneNetwork’s UCSC Genome Browser mirror (http://ucsc-
browser.genenetwork.org/) for visualization. Number of se-
quence tags was counted for each exon feature within Nrxn1.
TheentiredatacanbedownloadedfromGeneNetwork’shigh-
throughput sequence data sharing site at http://galaxy.gene-
network.org:8080/library. Additionally, read alignments can
also be visualized on the GeneNetwork Genome Browser.
QTL analysis for behavioral traits. To identify behavioral
phenotypes that may be downstream of Nrxn1 we used a
point-wise P-value of 0.01. We selected phenotypes that
correlated with marker rs6313030 (located on Chr 17 at
90.460122Mb within the Nrxn1 gene) and then analyzed
behavioral traits assayed in the BXDs using marker
regression. The behavioral phenotypes with QTLs on distal
Chr 17 are (1) prepulse inhibition, assayed by McCaughran
et al.
41 in a panel of 21 BXD strains (trait ID on Genenetwork
is 10396), (2) anxiety trait measure by time spent in open
quadrant of zero-maze, assayed in a larger panel of 57 BXD
strains
42 (trait ID 11696) and (3) handling induced convulsion
as an index of ethanol withdrawal severity, measured in 25
BXD strains
43 (trait ID 10065).
Gene–gene interaction analysis. To explore epistatic
associations between NRXN1 and GSK3B, we ﬁrst
extracted all markers in NRXN1 and GSK3B and in the
20kb ﬂanking regions from the MGS data set.
30 GAIN and
non-GAIN data sets
30 were combined and markers common
to both were used. Association tests and minor allele
frequency (MAF) were calculated using PLINK 2.050
44 and
markers with minor allele frequencies X0.05 were selected
(384 in NRXN1 and 17 in GSK3B). Sporadic missing
genotypes in these markers were imputed by MDRdt Beta
V0.4.3 (http://www.epistasis.org). Multifactor dimensionality
reduction (MDR) method was used to conduct gene–gene
interaction analyses (MDR 2.0 beta 8.1). The details of MDR
are described elsewhere.
24,45,46 We used two methods to
further ﬁlter the markers. One is the odds ratio ﬁlter
implemented in the MDR software, which uses the case
control ratio in the data set to deﬁne high-risk and low-risk
genotype combinations.
46–48 Using this approach, the top ﬁve
markers from each gene were selected. The other ﬁlter was
based on single marker association P-values in which tagged
SNPs
49 with association Pp0.15 in both genes were selected
(a total of 13 markers in the two genes). SNPs selected by
both methods were used for MDR analyses and best models
were generated based on a 10-fold cross-validation
consistency. In this study, we limited the search to a 2-loci
and 3-loci interaction model using SNPs from the ﬁrst and
second ﬁlters, respectively. The signiﬁcance of the best model
was evaluated by 10000 permutations (MDRpt 1.0 beta 2).
50
Additional bioinformatics tools. Gene ontology and
pathway enrichment analysis was done using DAVID 6.7
(http://david.abcc.ncifcrf.gov).
51,52 Protein–protein network
analysis was done using the protein interaction database
and network tool available on GeneMania (http://
www.genemania.org).
53 The protein network was based on
known physical interactions curated from 114 sources, and
the network was weighted by biological process.
Results
Genetic regulation of Nrxn1 exons. Nrxn1 has
widespread expression in the brain. We used microarrays
to measure its transcript at exon level resolution in the
hippocampus of 74 members of the BXD family. Additionally,
we measured expression in parental strains using RNA-seq.
The very deep coverage provided by the arrays and RNA-
seq uncovered signiﬁcant inter-exon variability in Nrxn1 that
may reﬂect alternative isoforms (Figure 1a). For example,
low expressing exons (exons 2, 6, 11 and 19) are located
within known splice sites
10,11 and the RNA-seq also showed
a potentially skipped exon (exon 4 of Refseq gene
NM_020252.3) (Figure 1b). To evaluate how tightly
expression of exons is coupled with one another, we
generated a correlation matrix of the exons and UTRs
based on expression variation across the BXD family
(Figure 1c). For the most part, exons form highly correlated
expression blocks indicating that they are regulated as a
single unit. The few exceptions are exons 1, 3, 11, 21, 22 and
the UTRs, which show poor correlation with most of the other
exons and may be alternatively spliced.
Nrxn1 expression is also highly variable across the strains
with exons varying from 1.5-fold to 10-fold in abundance
(Figure 1a). On average, the exons show a 2.5-fold variation
among the BXDs. To track down genetic sources of this
variation, we carried out eQTL mapping using conventional
linkage analysis tools and genotypes embedded in GeneNet-
work. The UTRs and canonical exons of Nrxn1 are partly
controlledbypolymorphismsnearthegeneitself(so-calledcis
eQTL) and partly by trans-acting polymorphisms (Figure 1b).
A tightly correlated set of exons map as a cis eQTL to distal
Chr 17 within 0.5 Mb of Nrxn1 itself. These exons are also
strongly co-modulated by a trans regulatory QTL on mid-
Chr 8. Several exons that are putatively subjected to splicing
(for example, exons 1, 8, 11 and 21) are not modulated by
either the cis or Chr 8 trans loci. Additionally, there are trans
eQTLs on other Chrs associated with a minor set of exons
(Supplementary Figure S1). For example, exons 12, 16 and
19 have trans eQTLs in mid-Chr 2 and exons 1, 3, 11 and 22
havetranseQTLsonChr12.Theseﬁndingsindicatealevelof
isoform speciﬁcity and joint eQTL control that corresponds
to the complex splicing signatures in the exon co-expression
matrix.
Sequence polymorphism in Nrxn1 between C57BL/6J
and DBA/2J. The maternal parent of the BXD strains, B6,
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as the mouse reference genome. The paternal strain, D2,
has recently been resequenced at high density using
next-generation systems (brief description of the 100x
resequencing of the D2 genome is provided in
Supplementary methods).
34 This now makes it possible to
carefully review all sequence variants in and around Nrxn1 to
help identify variants that are candidates for the cis-effect on
expression. We found numerous sequence differences
between the B6 (B) and D2 (D) alleles. There are over
2900 SNPs in Nrxn1. Of these, only nine are in the 30 UTR,
two are synonymous mutations in exons 5 and 17, and the
remaining SNPs are in introns. In all, 15 SNPs in introns have
potentially high impact based on overlap with predicted
functional elements in conserved regions of introns
54
(Supplementary Table S1). The introns also contain a large
number of insertions and deletions (deﬁned as insertion or
deletion in D relative to B). There are 436 deletions and 340
insertions ranging in length from 1 to 2418bp (Figure 1b and
Supplementary Table S1). Although none of these overlap
canonical exons, such structural variations can have
signiﬁcant effects on gene expression. We selected a 74-
bp insertion and a 107-bp deletion located in intron 17, which
harbors the alternative promoter for the b-variant
10,11 and
conﬁrmed the variants by PCR ampliﬁcation (Supplementary
Figure S2).
Genetic analysis of Nrxn1 co-expression network. To
elucidate a co-expression network associated with the Nrxn1
transcript, we ranked the top 1000 correlates of Nrxn1
expression from the pool of 1.2 million probe sets. These
represent transcripts that have coordinated expression with
Nrxn1 and are potential partners in cellular functions. These
top covariates (Pearson product r4|0.6|, Po3.7 10
 9)
correspond to 572 known genes (Supplementary Material B).
Consistent with the synaptic involvement of Nrxn1, this set of
Figure 1 Expression of neurexin 1 (Nrxn1) exons in mouse hippocampus. (a) Exon-level expression of Nrxn1 was measured by direct sequencing of mRNA (upper bar
chart;errorbarsares.d.)andbyusingexonarrays(lowerboxplots).Expressionvaluesareonalog2scale(yaxis).Thereissigniﬁcantvariationinexpressionofexonsamong
the BXDs. On average, expression varies 2.5-fold within exons. Based on RNA sequencing, exons 2 and 6 have low expression and exon 4 is skipped (there are no array
probesetsforthese).(b)ThegenemodeldepictedisbasedonRefSeqgeneNM_020252.3.Locationofthe50 UTRforb-Nrxn1isshowninintron17(arrow)andknownsplice
sitesareindicatedabove(1–5).Approximatelocationsofinsertionanddeletion(indel)variantsthatarelargerthan10bpsareshownbelow(linesfordeletionsandtrianglesfor
insertions in D2). Expression QTLs on chromosomes (Chrs) 8 (trans) and 17 (cis) are shown as heat maps for each exon and UTR. Allele from the DBA/2J parent has the
positive effect on Chr 8 (red) while allele from the C57BL/6J parent has the positive effect on Chr 17 (blue). (c) The correlation matrix displays pair-wise correlations between
the UTRs and exons in the BXDs. The lower cells are Pearson product moment and upper cells are Spearman ranked correlations. Exons 5–20 form a tightly correlated
expression block (exon 11 being the exception). Correlation between the distal and proximal parts of the gene is generally low.
Cross-species genetic analysis of neurexin 1 expression
K Mozhui et al
4
Translational Psychiatrygenes is enriched in synapse-related transcripts and genes
known to directly interact with Nrxn1 (for example, Cask and
Nlgn1) (Supplementary Material B). More interestingly,
there is also enrichment in genes that are part of the WNT,
axon guidance, mitogen-activated protein kinase and ErbB
signaling pathways (for example, Gsk3b, Akt1 and Nrg3) and
this suggests that there is close interaction between Nrxn1
and downstream cellular signaling. We also used the Genetic
Association Database (http://geneticassociationdb.nih.gov)
and were able to extract a set of 20 schizophrenia
candidate genes (Figure 2a) in our top 572 Nrxn1
covariates (Benjamini corrected enrichment Po0.001).
eQTL mapping of the co-expression network members
detected regulatory loci (that is, trans eQTL hotspots) on (1)
mid-Chr 2 (67–77Mb), (2) proximal Chr 6 (2–20Mb) and (3)
mid-Chr 8 (50–85Mb). The ﬁrst principal component (PC1)
summarization of these highly correlated transcripts, also
called an eigengene,
55 retained this whole-genome eQTL
pattern. This is illustrated by the eigengene for the tightly
correlated schizophrenia network: the PC1 of the 20
transcripts accounts for B55% of the total variance and maps
as suggestive QTLs to Chrs 2, 6 and 8 (Figure 2b). PC1 of the
Nrxn1 exons (accounting for B50% of the total variance) has
signiﬁcant QTLs on Chrs 8 and 17, and suggestive QTL on
Chr 2 (Figure 2c). Although exons 7, 8, 11 and 12 of Nrxn1
map as weak trans eQTL to proximal Chr 6 (Supplementary
Figure S1), this association does not reach the suggestive
threshold in the summarized map. Based on the comparison
of eQTLs, Nrxn1 is not likely to be a QTL hotspot for the
expression traits. Instead, the co-expression network is
modulated mainly by eQTL hotspots on Chrs 2, 6 and 8. A
portion of the variance in Nrxn1 comes from these trans-
effects that connect Nrxn1 to the network.
Mouse behavioral phenotypes that map close to
Nrxn1. We then asked whether mouse phenotypes that
may be concordant with human traits are associated with the
Nrxn1 locus. GeneNetwork maintains a database of over
2000 phenotypes collected from the BXDs. We speciﬁcally
searched this database for behavioral traits that have linkage
with markers near Nrxn1. We found three such traits that
have signiﬁcant point-wise QTLs on distal Chr 17. First,
PPI to acoustic startle
41 mapped to distal Chr 17 with a
point-wise P¼0.0003 (LRS¼16) (Figure 2d). Second,
anxiety phenotype assayed on the zero-maze
42 mapped to
distal Chr 17 with point-wise P¼0.005 (LRS¼10.5). The
Figure 2 Overlap of co-expression and behavioral QTLs. (a) An enriched set of twenty schizophrenia candidate genes was extracted from the covariates of neurexin 1
(Nrxn1) in the mouse hippocampus. These transcripts form a highly interconnected co-expression network with Nrxn1.( b) The co-expression network is modulated by
expressionQTLs(eQTLs)onchromosomes(Chrs)2,6and8.ThisisillustratedbytheQTLmapfortheﬁrstprincipalcomponentsummarization(PC1)ofthe20schizophrenia
candidates. The x axis represents Chrs 1 to X and the y axis shows the LRS score. The horizontal lines indicate the genome-wide suggestive and signiﬁcant thresholds.
(c) PC1 of the Nrxn1 exons has signiﬁcant QTLs on Chrs 8 and 17, and suggestive QTL on Chr 2. Location of Nrxn1 in the cis eQTL is depicted by the triangle. Mouse
behavioral traits that map close to the Nrxn1 locus at signiﬁcant point-wise P-values (Po0.01) are prepulse inhibition (d), anxiety trait (e) and ethanol response (f).
Overlapping QTL locations are highlighted.
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genome-wide QTL pattern with additional QTLs on mid-Chr 8
(LRS¼14; point-wise P¼0.0007) and Chr 2 (LRS of 8.4;
point-wise P of 0.01) (Figure 2e). Finally, handling-induced
convulsion as an index of alcohol withdrawal severity
43
mapped to distal Chr 17 with a point-wise P of 0.007
(LRS¼9.6) (Figure 2f).
We note that the behavioral traits also have QTLs that are
distinct from the QTLs associated with Nrxn1 and its co-
expression network. The associations between the QTLs and
multi-level phenotypes presents a complex genetic structure
and the effect of Nrxn1 on the behavior traits can either be
directly mediated by the cis eQTL, or more likely, is
transmitted via the co-expression network with major con-
tributions by the set of trans eQTLs.
Cross-species analysis of the Nrxn1 covariates. We next
examined if correlations at the mRNA level are preserved
across species. Our aim was to identify strong and consistent
correlations that are conserved in both mice and humans and
that may be novel functional and genetic associates of
Nrxn1. We used a human forebrain expression data set
39,40
and extracted the top 1000 covariates of NRXN1 (Pearson
product r4|0.55|, Po3 10
 7). This corresponds to 767
unique genes (Supplementary Material B). Of these 767
genes, only 42 overlap with the 572 co-expressed genes
in mice and have conserved correlations with NRXN1 in
human forebrain as well as in the mouse hippocampus
(Supplementary Table S2). This includes GSK3B and
NTNG1, which are both part of the Nrxn1 primed schizo-
phrenia network derived from the mouse covariates.
56,57
To explore protein interactions that may be encrypted in the
mRNA co-expression set, we extracted a protein–protein
interaction network from the list of 767 transcript covariates
(Figure 3a). In all, 261 out of the 767 query genes (34%)
formed a highly interconnected protein network that incorpo-
rated most of the conserved transcript correlates of NRXN1
including GSK3B, and also several other schizophrenia
candidates. GSK3B has diverse roles in cellular signaling in
the brain
57–59 and we examined the expression covariance of
GSK3B and NRXN1 in a number of different mouse
and human brain regions and found generally strong correla-
tions between the two (Supplementary Figure S3). The
strong genetic correlation suggests interactions between
NRXN1 and GSK3B and places NRXN1 as a synaptic gene
that may also function as a gateway to cellular signaling
cascades.
Test for epistasis between NRXN1 and GSK3B in human
schizophrenia. We hypothesize that there is close
functional relation between NRXN1 and GSK3B. We tested
for gene–gene interactions in human using the MGS data set
that has 2255 schizophrenia cases and 2641 controls.
30 We
found signiﬁcant 2-loci interaction between rs4563262
(NRXN1) and rs4340737 (GSK3B) with a permuted
P¼0.012 (Figure 3b). Using a 3-loci model, there was
signiﬁcant interaction between rs6736816 and rs9309200 in
NRXN1, and rs9826659 in GSK3B (permuted P¼0.0373)
(Table 1). No covariate sex effect was found. Among the top
ﬁve SNPs in the two genes, we also found that rs4340737
in GSK3B and rs9309200 in NRXN1 are the only two SNPs
that showed signiﬁcant associations with schizophrenia
(P¼0.0171 for rs4340737 and P¼0.0293 for rs9309200).
Figure 3 Deriving protein–protein and genetic interactions from co-expressed genes. (a) The co-expression network for neurexin 1 (NRXN1) in the human brain was
organized based on known protein–protein interactions. This resulted in a single large network that connected 261 out of 767 co-expressed transcripts. The network
incorporates several known schizophrenia candidates (shaded green) and several conserved covariates of NRXN1, that is, are correlated with NRXN1 in both human and
mouse (shaded orange). NRXN1 and glycogen synthase kinase 3 beta (GSK3B) are part of this protein network (shaded red). (b) Test for epistasis using the multifactor
dimensionalityreductionmethodfound signiﬁcantinteractionbetweenrs4563262inNRXN1andrs4340737inGSK3B.Distributionof cases(left bar incell)andcontrols(right
bar in cell) stratiﬁed by multilocus genotype. Each multifactorial cell is labeled as ‘high risk’ or ‘low risk’. Average balanced prediction accuracy for the model was 51.85%,
permuted P¼0.0123.
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for schizophrenia. Our study demonstrates that gene co-
expression analysis can effectively select related disease
candidates and epistatic partners. We therefore used
evidence from the co-expression analysis and mouse
behavioral endophenotypes to further prioritize other
potential candidates. For this, we considered genes in the
MGS data set that were nominally associated with
schizophrenia. The study by Shi et al.
30 generated a list of
1202 SNPs in the European-American cohort and a list of
997 SNPs in the African-American cohort with association
Po0.001. We mined the SNP lists for nearby genes with
mouse homologues that are among the top covariates of
Nrxn1 in the mouse hippocampus. Additional functional
evidence was gathered from knockout studies and gene
ontology. On the basis of this, we identiﬁed 30 genes that are
nominally associated with schizophrenia and are co-
expressed with Nrxn1. Several of these are already known
candidates for neuropsychiatric disorders including
schizophrenia, autism, attention deﬁcit hyperactivity disorder
(ADHD), and bipolar disorder (Table 2).
60–73 Strikingly, 10 out
of the 30 genes are also nominally associated with substance
dependence and nicotine addiction.
74,75 In the mouse,
deletion of six of these candidates (CTNND2, DMN,
GSK3B, NRCAM, PLCB1 and RIMS1) lead to behavioral
changes related to PPI, social and cognitive functions,
hyperactivity, fear learning and anxiety-related traits.
76–83
Among the novel genes in Table 2, we highlight Pleckstrin
andSec7 domaincontaining 3 (PSD3)asboth a potential new
candidate for schizophrenia and a candidate for the trans-
effect associated with the co-expressed transcripts in the
mousebrain.Thisgenehashighexpressioninthebrainandis
located in mid-Chr 8 within the trans eQTL for the Nrxn1
exons. Expression of Psd3 is associated with a signiﬁcant cis
eQTL in the BXDs and is also strongly correlated with Nrxn1
(Supplementary Figure S4).
Discussion
Synopsis. Nrxn1 is highly polymorphic and is associated
with signiﬁcant variation in expression among mice. We have
exploited this variation to trace co-expression networks and
eQTLs that link Nrxn1 with other genes and also with higher
order behavioral phenotypes. GSK3B is among the strongest
and most consistent covariates of NRXN1 in both mice and
humans and we detected a signiﬁcant epistatic interaction
between these genes that modulates schizophrenia risk.
This cross-species analysis also highlights novel candidates
for schizophrenia in human, especially PSD3.
Sub-transcript level analysis of gene expression
regulation. For a ﬁne-scale analysis of Nrxn1, we have
treated each exon, intron and the UTRs as discrete
expression units that can be individually subjected to
genetic analysis. This revealed some level of complexity in
transcript regulation. For instance, exons 8, 11 and 21 show
low correlation with other exons and are also associated with
distinct eQTLs. Aside from these exceptions, the majority of
exons have tightly correlated expression, partly due to
shared modulation by two prominent eQTLs—one a cis
eQTL at Nrxn1, and the other, a trans eQTL on mid-Chr 8.
The mid-Chr 8 trans eQTL also modulates several key
genes correlated with Nrxn1 including Psd3, Gsk3b, Snap25
and Kpna3. This interval corresponds to human 8p21, a
region that contains many genes linked to brain develop-
mental and psychiatric disorders.
84 Polymorphisms in this
region in humans may also have trans-regulatoryeffect on the
expression of other schizophrenia susceptibility genes.
85 In a
striking concordance between mouse and human, this part of
mouse Chr 8 is also a QTL hot spot for brain structural traits in
the BXDs and is linked to variations in the volume of the
amygdala, hippocampus, cerebellum and striatum.
86,87 Lo-
cated in this mid-Chr 8 QTL is Psd3, a gene that is modulated
by a cis eQTL and is also co-expressed with Nrxn1. In the
human MGS data set, SNPs near PSD3 are nominally
associated with schizophrenia (P¼0.00007). Although little
is currently known about the function of PSD3, the converging
evidence from multiple sources makes this gene a high-
priority candidate for the eQTL in mouse and a novel
candidate for schizophrenia in human.
Variation in Nrxn1 expression may inﬂuence
schizophrenia endophenotypes. In the BXDs, PPI to
acoustic startle maps to distal Chr 17 close to the Nrxn1
locus. PPI is a classic endophenotype that models sensory
gating deﬁcits in schizophrenia patients,
88 and polymorphisms
in Nrxn1 are strong candidates with compelling face
validity. Consistent with association to schizophrenia,
deletion of Nrxn1a in mice results in decreased PPI.
23
However, in this knockout, social behavior and anxiety traits
are unaffected .
23
Unlike studies using gene knockouts, we have evaluated
naturally occurring variants that will generally have more
subtleeffectsonphenotypes.MostoftheSNPsandinsertions
and deletions in Nrxn1 are intronic and are unlikely to cause
Table 1 Multilocus epistatic interaction models between NRXN1 and GSK3B
No. of loci Best model Testing balance
accuracy (%)
Cross-validation
consistency
10000 permutation
P-value
2 rs4563262 (NRXN1) 51.85 10/10 0.0123
rs4340737 (GSK3B)
3 rs6736816, rs9309200 (NRXN1) 51.86 10/10 0.0373
rs9826659 (GSK3B)
Abbreviations: GSK3B, glycogen synthase kinase 3 beta; NRXN1, neurexin 1.
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Translational Psychiatrygene disruption. However, these more moderate variants
model the type of variation seen in human populations. A
detailed analysis of structural variations in the NRXN genes in
human has found a range of deletions and duplications.
89 The
deletions in NRXN1, particularly those that span exons, are
stronglyassociatedwithschizophrenia.Additionally,thereare
possible associations with other psychiatric conditions and
alcoholismthatindicatepleiotropiceffectsofNRXN1.
89Thisis
consistent with our ﬁndings in mouse in which QTLs for
ethanol response and anxiety map near Nrxn1.
Potential functional and epistatic partners: Nrxn1 and
Gsk3b. Hundreds of susceptibility variants have been
identiﬁed for schizophrenia in recent large-scale genomic
studies. Associated genes fall into diverse functional
categories and this supports the impressive genetic
heterogeneity of complex neuropsychiatric diseases.
90,91
The approach we have taken here is to use a population
model and exploit endogenous variations in a high-priority
candidate as a starting point for a systematic gene-to-
phenotype analysis. NRXN1 has been repeatedly linked to
schizophrenia and autism
15–19 and as we show, a co-
expression network primed by this gene captures other
genes that work closely with Nrxn1 and are involved in
disease pathway.
Co-expression and eQTL analyses led us to genes already
linked to Nrxn1 (for example, Cask, Nlgn1, g-aminobutyric
acid and glutamate receptors), and also led us to novel genes
that have less obvious, but potentially interesting links to
Nrxn1. Gsk3b is one such gene that we detected and then
validated as a novel genetic partner of Nrxn1. GSK3B has
diverse functions in the cell, including synaptic and intracel-
lular signal transduction
57–59 and could therefore be a conduit
between the synaptic role of NRXN1 and cell signaling.
Supporting this hypothesis, we found signiﬁcant genetic
interactions between SNPs in NRXN1 and GSK3B that
indicate that susceptibility to schizophrenia can be modiﬁed
toanextentbythecombination ofallelesinthetwo genes.For
example, in the 2-loci model, the AA genotype at rs4563262
(NRXN1) and the AG and GG genotypes at rs4340737
(GSK3B) interact to increase or decrease vulnerability.
Despitethegeneticinteractions,toourknowledge,nostudy
has yet demonstrated direct physical link between NRXN1
and GSK3B. However, the presynaptic region is a potential
locus of cellular interaction between the two proteins. GSK3B,
in addition to its many functions in cell signaling, also
modulates presynaptic vesicle release by phosphorylating
the voltage-dependent calcium channels and reducing in-
tracellular Ca
2þ levels.
59 It also regulates the development of
the active zone—the site of vesicle fusion and neurotransmit-
ter release.
92 NRXN1, a predominantly presynaptic protein,
modulates releasebyselectively actingonvoltage-dependent
calcium channel (P/Q and N type), possibly by modifying the
coupling of Ca
2þ channels to release-ready vesicles.
13
Variants of NRXN1 and GSK3B may therefore have a
collective inﬂuence on the synaptic environment and conse-
quently on disease susceptibility. Both the genetic interaction
and a potential molecular interaction are consistent with a
model in which neurotransmission and intracellular signaling
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